Cures & Capital

Hello and welcome to Cures & Capital - the podcast on value creation in biotech and pharma. Together, we are going to dive deep into the world of biotech and pharma to tackle the holy grail - how do we improve return on investment from drug innovation and deliver transformative therapies to patients, efficiently and sustainably. Hosted by Martin Slezak & Simon Birksø Disclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.

Cures & Capital is a business podcast hosted by Martin Slezak and Simon Birksø, with 19 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Martin Slezak and Simon Birksø hosts Cures & Capital, a business show with 19 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #19

  Inside Eli Lilly's Transformation and Rise to the Top with Jan Lundberg

  Mar 18, 202655 minS1

  <p>In this episode, we speak with Jan Lundberg – former President of Lilly Research Laboratories and Head of R&D at Eli Lilly and Company.</p><p>With a career spanning academia, biotech, and big pharma, Jan has contributed to the development of more than 30 approved medicines, including Brilinta, Iressa, Nexium, Taltz, Trulicity, Verzenio, and Tirzepatide (Mounjaro). He also played a central role in one of the most remarkable growth stories in the industry.</p><p>We explore what it really takes to turn around an R&D organization – from inheriting late-stage failures and pipeline setbacks to rebuilding decision-making, culture, and...

  ListenShow Notes
• 

  Cures & Capital

  How Wall Street Really Values Biotech with Hartaj Singh

  Dec 18, 20251h 27mS0

  <p>How do investors really value biotech? Former hedge fund investor and biotech analyst Hartaj Singh explains how Wall Street thinks about risk, biology, clinical trials, and uncertainty - and why biotech valuation is both art and formula.</p><p>Hartaj Singh on LinkedIn:</p><p>https://www.linkedin.com/in/hartaj-s-35614670/</p><p><br/></p><p>Check out Hartaj's newsletter:</p><p>The Biotech Capital Compass - https://hartajsingh1.substack.com/</p><p><br/></p><p>Subscribe to the Cures & Capital podcast on YouTube, Apple Podcasts, and Spotify!</p><p>Make sure to follow us on LinkedIn:</p><p>...

  ListenShow Notes
• 

  Episode #17

  Advanced Drug Modalities with Jeff Holder & Adam Siebert: From Science to Real-World Impact

  Nov 26, 20251h 6mS1

  <p>In this episode, we talk to Jeff Holder and Adam Siebert, Partners and Managing Directors at L.E.K. Consulting, about the rapidly evolving world of advanced drug modalities. <br/><br/>With years of experience advising clients across the life sciences industry, Jeff and Adam sit at the intersection of cutting-edge science and the real-world constraints of getting medicines to patients. Together, we unpack the past, present and future of advanced drug modalities, the science and the strategic implications behind them, and explore what it really takes to bring these breakthroughs to market.</p><p>If you want to c...

  ListenShow Notes
• 

  Cures & Capital

  Sheila Gujrathi, MD: How to elevate female leaders and underrepresented voices in biopharma

  Nov 5, 20251h 1mS0

  <p>In this episode of Cures & Capital, Dr. Sheila Gujrathi — biotech entrepreneur, investor, and former CEO of Gossamer Bio — shares her perspective on how to elevate female leaders and underrepresented voices in biopharma.</p><p>She discusses lessons from her 25+ years leading companies and investments, and why inclusive leadership is key to innovation and value creation.</p><p>We also dive into her book, The Mirror Effect, and her mission to inspire the next generation of women in biotech.</p><p>Check out Sheila's book (released Nov. 4, 2025) on her website:</p><p>https://sheilagujrathimd.com/book/ </p><p><br/></p><p>🎙️...

  ListenShow Notes
• 

  Episode #15

  Scott Berry on Rethinking Clinical Trials: Bayesian Design, Adaptivity, and Smarter Decisions

  Oct 15, 20251h 19mS1

  <p>In this episode, we talk to Scott Berry, President and Senior Statistical Scientist at Berry Consultants - a pioneer in adaptive and Bayesian clinical trial design. With more than 25 years of experience designing trials for pharma, biotech, and government agencies, Scott has helped reshape how we think about learning in drug development.<br/><br/>We explore what it really means to “learn as you go” in clinical trials - from the limitations of the traditional frequentist model to the promise of adaptive and Bayesian designs that evolve with the data. Scott breaks down why these methods can de-risk programs, opti...

  ListenShow Notes

Recent guests on Cures & Capital. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.